Home Cart 0 Sign in  
X

[ CAS No. 39903-01-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 39903-01-0
Chemical Structure| 39903-01-0
Chemical Structure| 39903-01-0
Structure of 39903-01-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 39903-01-0 ]

Related Doc. of [ 39903-01-0 ]

Alternatived Products of [ 39903-01-0 ]

Product Details of [ 39903-01-0 ]

CAS No. :39903-01-0 MDL No. :MFCD09744143
Formula : C5H5BrN2O Boiling Point : -
Linear Structure Formula :- InChI Key :YQADLKDQAXAIKW-UHFFFAOYSA-N
M.W : 189.01 Pubchem ID :11694041
Synonyms :

Calculated chemistry of [ 39903-01-0 ]

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 2.0
Molar Refractivity : 38.36
TPSA : 59.14 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.86 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.25
Log Po/w (XLOGP3) : 0.84
Log Po/w (WLOGP) : 1.14
Log Po/w (MLOGP) : 0.37
Log Po/w (SILICOS-IT) : 0.91
Consensus Log Po/w : 0.9

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.03
Solubility : 1.75 mg/ml ; 0.00924 mol/l
Class : Soluble
Log S (Ali) : -1.66
Solubility : 4.09 mg/ml ; 0.0216 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.95
Solubility : 2.15 mg/ml ; 0.0114 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.76

Safety of [ 39903-01-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 39903-01-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 39903-01-0 ]
  • Downstream synthetic route of [ 39903-01-0 ]

[ 39903-01-0 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 21594-52-5 ]
  • [ 39903-01-0 ]
YieldReaction ConditionsOperation in experiment
98% Heating / reflux 2:
6-Bromo-3H-oxazolo[4,5-b]pyridin-2-one (21.5 g, 100 mmol) was suspended in NaOH solution (2N, 250 mL, 500 mmol).
The mixture was refluxed overnight and a clear solution was obtained.
After cooling to room temperature, the reaction solution was neutralized to pH ~7.
A lot of CO2 was released and also precipitate was observed.
The product was filtered, washed with water, and dried under high vacuum to provide 2-amino-5-bromo-pyridin-3-ol as an off-white solid (17.8 g, 98percent yield).
98%
Stage #1: Heating / reflux
Stage #2: Acidic aqueous solution
6-Bromo-3H-oxazolo[4,5-b]pyridin-2-one (21.5 g, 100 mmol) was suspended in NaOH solution (2N, 250 mL, 500 mmol). The mixture was refluxed overnight and a clear solution was obtained. After cooling to room temperature, the reaction solution was neutralized to pH ~7. A lot of C02 was released and also precipitate was observed. The product was filtered, washed with water, and dried under high vacuum to provide 2-amino-5-bromo-pyridin-3-ol as an off-white solid (17.8 g, 98percent yield).
80%
Stage #1: Heating / reflux
Stage #2: With hydrogenchloride In water
To a solution of 6-bromo-3H-oxazolo[4,5-.pound.]pyridin-2-one (28.0 g, 130 mmol) in MeOH (280 mL) was added a solution of NaOH (28.1 g, 703 mmol) in water (280 mL). The mixture was heated to reflux overnight. The organic solvent was removed in vacuo and the aqueous mixture was adjusted to pη 5-6 with 12 M HCl. The resulting precipitate was isolated by filtration, washed with Et2ψ and dried under vacuum at 50 °C overnight to give the title compound (19.6 g, 80percent) as a gray solid: 1H NMR (500 MHz, DMSO-cfc) δ 10.1 (s, IH), 7.46 (d, J= 1.5 Hz, IH), 6.88 (s, IH), 5.70 (s, 2H); ESI MS m/z 190 (M + H)+.; To a suspension of 6-bromo-3H-oxazolo[4,5-]pyridin-2-one (20.0 g, 93.0 mmol) in methanol (200 mL) was added NaOH (20.0 g, 500 mmol) in H2O (200 mL) and the mixture was heated to reflux overnight. After cooling, methanol was removed in vacuo. The aqueous residue was acidified with 3N HCl to pH 5-6. The resulting precipitate was collected by filtration, and dried overnight under vacuum at 45 0C to give the title compound as a tan solid (16.4 g, 93percent): 1H NMR (300 MHz, DMSO-^) δ 10.03 (s, IH), 7.47 (d, J= 2.0 Hz, IH), 6.93 (d, J= 2.0 Hz, IH), 5.72 (s, 2H); ESI MS m/e 188 (M + H)+.
80%
Stage #1: at 100℃; for 6 h;
Stage #2: With hydrogenchloride In water at 5℃;
[00104] As shown in step 4-iii of Scheme 20, Compound 1012 (34 g, 158.1 mmol) was diluted with 10percent NaOΗ(aq) (500 mL), and the resulting mixture was stirred at 100 0C for 6 h. The reaction was cooled to 5 0C, and 6 N HCl was added until a precipitate formed (ca. pH 10). The solid was collected in a fritted funnel, washed with water (200 mL), and dried under vacuum to afford 2-amino-5-bromo-3-hydroxypyridine (Compound 1013, 24.0 g, 80percent yield) as a tan solid: ESMS (M+H) 189, 191; 1H NMR (DMSO-d6) δ 7.5 (s, IH), 6.9 (s, IH), 5.7 (br, 2H).
80%
Stage #1: With sodium hydroxide In water at 100℃; for 6 h;
Stage #2: With hydrogenchloride In water
As shown in step 4-iii of Scheme 20, Compound 1012 (34 g, 158.1 mmol) was diluted with 10percent NaOΗ(aq) (500 mL), and the resulting mixture was stirred at 100 0C for 6 h. The reaction was cooled to 5 0C, and 6 N HCl was added until a precipitate formed (ca. pH 10). The solid was collected in a fritted funnel, washed with water (200 mL), and dried under vacuum to afford 2-amino-5-bromo-3-hydroxypyridine (Compound 1013, 24.0 g, 80percent yield) as a tan solid: ESMS (M+H) 189, 191; 1H NMR (DMSO-d6) δ 7.5 (s, IH), 6.9 (s, IH), 5.7 (br, 2H).

Reference: [1] Patent: US2006/46991, 2006, A1, . Location in patent: Page/Page column 33-34
[2] Patent: WO2006/21886, 2006, A1, . Location in patent: Page/Page column 64; 65
[3] Heterocycles, 2001, vol. 55, # 7, p. 1329 - 1345
[4] Heterocycles, 1995, vol. 41, # 12, p. 2799 - 2810
[5] Tetrahedron Letters, 2014, vol. 55, # 9, p. 1528 - 1531
[6] Patent: WO2007/67416, 2007, A2, . Location in patent: Page/Page column 56; 57; 92; 95
[7] Patent: WO2010/96389, 2010, A1, . Location in patent: Page/Page column 42-43; 44
[8] Patent: WO2010/135014, 2010, A1, . Location in patent: Page/Page column 50-51
[9] Patent: WO2016/97918, 2016, A1, . Location in patent: Page/Page column 66
  • 2
  • [ 16867-03-1 ]
  • [ 39903-01-0 ]
Reference: [1] Archiv der Pharmazie, 2011, vol. 344, # 3, p. 158 - 164
[2] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 828 - 835
[3] Tetrahedron Letters, 2014, vol. 55, # 9, p. 1528 - 1531
[4] Patent: WO2016/97918, 2016, A1,
[5] Patent: US4022897, 1977, A,
  • 3
  • [ 35486-42-1 ]
  • [ 12775-96-1 ]
  • [ 39903-01-0 ]
Reference: [1] Patent: US4033975, 1977, A,
  • 4
  • [ 12775-96-1 ]
  • [ 38185-55-6 ]
  • [ 39903-01-0 ]
Reference: [1] Patent: US4033975, 1977, A,
  • 5
  • [ 60832-72-6 ]
  • [ 39903-01-0 ]
Reference: [1] Heterocycles, 2001, vol. 55, # 7, p. 1329 - 1345
[2] Heterocycles, 1995, vol. 41, # 12, p. 2799 - 2810
[3] Tetrahedron Letters, 2014, vol. 55, # 9, p. 1528 - 1531
[4] Patent: WO2016/97918, 2016, A1,
  • 6
  • [ 754230-78-9 ]
  • [ 39903-01-0 ]
Reference: [1] Archiv der Pharmazie, 2011, vol. 344, # 3, p. 158 - 164
  • 7
  • [ 24016-03-3 ]
  • [ 39903-01-0 ]
Reference: [1] Archiv der Pharmazie, 2011, vol. 344, # 3, p. 158 - 164
  • 8
  • [ 106840-72-6 ]
  • [ 39903-01-0 ]
Reference: [1] Patent: WO2016/97918, 2016, A1,
  • 9
  • [ 874-24-8 ]
  • [ 39903-01-0 ]
Reference: [1] Patent: US4022897, 1977, A,
  • 10
  • [ 100-39-0 ]
  • [ 39903-01-0 ]
  • [ 754230-78-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 18, p. 6342 - 6363
  • 11
  • [ 59154-46-0 ]
  • [ 39903-01-0 ]
  • [ 894852-01-8 ]
YieldReaction ConditionsOperation in experiment
84% With potassium carbonate In acetone for 18 h; Heating / reflux a) 7-Bromo-2,2-dimethyl-4H-pyrido[3,2-] [ 1 ,4]oxazin-3 -one; To a mixture of 2-amino-5-bromopyridin-3-ol (0.500 g, 2.64 mmol) and K&2CO3 (1.09 g, 7.93 mmol) in acetone (11.0 niL) was added ethyl bromoisobutyrate (0.50 mL, 3.4 mmol). The solution was stirred under N2 for 18 h and then heated to reflux. After 18 h, the solution was cooled and concentrated. The light-pink, sweet-smelling solid was dissolved in CH2Cl2 (50 mL) and MeOH (5 mL). The solution was diluted with H2O (150 mL) and then washed with CH2Cl2 (3 x 75 mL). The combined organic layers were washed with brine (2 x 100 mL), dried (Na2SO4) and concentrated to yield the title compound (0.57 g, 84percent) as an off-white solid: 1H NMR (300 MHz, DMSO-J,*) δ 11.39 (s, IH), 8.03 (d, J=1.2 Hz, IH), 7.66 (d, 0.9 Hz, IH), 1.43 (s, 6H).
Reference: [1] Patent: WO2007/53131, 2007, A2, . Location in patent: Page/Page column 130
  • 12
  • [ 107-20-0 ]
  • [ 39903-01-0 ]
  • [ 1379358-48-1 ]
YieldReaction ConditionsOperation in experiment
92% at 60℃; [00188] 2-Amino-3-hydroxy-5-bromopyridine (Heterocycles, 1995, 41, 2799) (124 mg, 0.65 mmol) was dissolved in EtOH (3 niL) and added chloroacetaldehyde (0.2 niL, 1.3 mmol, 50percent in water) and the resulting solution heated at 60 °C overnight. The solvents were then removed and the solids were crystallized from acetone to give 6-bromoimidazo[l,2-a]pyridin-8-ol hydrochloride (151 mg, 92percent).
92% at 60℃; 2-Amino-3-hydroxy-5-bromopyridine (Heterocycles, 41 :2799 (1995)) (124 mg, 0.65 mmol) was dissolved in EtOH (3 niL) and added chloroacetaldehyde (0.2 mL, 1.3 mmol, 50percent in water) and the resulting solution heated at 60 0C overnight. The solvents were then removed and the solids were crystallized from acetone to give 6-bromoimidazo[l,2-a]pyridin-8-ol hydrochloride (151 mg, 92percent)
Reference: [1] Patent: WO2009/155389, 2009, A1, . Location in patent: Page/Page column 88-89
[2] Patent: WO2009/155388, 2009, A1, . Location in patent: Page/Page column 98-99
  • 13
  • [ 39903-01-0 ]
  • [ 122-51-0 ]
  • [ 1260863-86-2 ]
YieldReaction ConditionsOperation in experiment
60% for 5 h; Reflux Preparation 56-Bromo-oxazolo[4,5-b]pyridine[00122] 2-Amino-5-bromo-3-hydroxypyridine (200 mg, 1.06 mmol) is dissolved in 3 ml of triethylortoformate and a catalytic amount of p-toluenesulfonic acid is added. The mixture is heated to reflux for 5 h, then cooled, diluted with DCM and washed with saturated sodium bicarbonate solution. The organic phase is dried over anhydrous sodium sulfate and evaporated to dryness. The residue is purified by flash column chromatography to afford 212 mg (60percent) of the title compound.
Reference: [1] Patent: WO2011/15343, 2011, A1, . Location in patent: Page/Page column 40
  • 14
  • [ 24424-99-5 ]
  • [ 39903-01-0 ]
  • [ 1207175-73-2 ]
YieldReaction ConditionsOperation in experiment
98% With triethylamine In dichloromethane at 20℃; for 18 h; Example 1 The preparation of 5-bromo-3-hydroxy-2-tert-butyloxycarbonylamino pyridine (0038) To a solution of 2-amino-3-hydroxy-5-bromopyridine (10.0 g, 53.0 mmol) and Et3N (10 mL, 71.8 mmol) in dichloromethane (100 mL) was added Boc2O (12.7 g, 58.4 mmol). The mixture was stirred at room temperature for 18 h and continued to stir for 30 min after the addition of 150 ml water. The reaction mixture was filtrated off through celite. The organic layer was separated and the aqueous layer was extracted with 150 dichloromethane. The combined organic layers were washed with saturated NaCl aqueous solution (2×100 mL) and then dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the obtained residue was triturated in hexane (100 mL), filtrated, and dried under vacuum to afford 15.0 g 5-bromo-3-hydroxy-2-tert-butyloxycarbonylamino pyridine as a white solid, with a yield of 98.0percent. (0039) 1H NMR (400 MHz, CDCl3): δ 7.98 (d, J=2.0 Hz, 1H), 7.58 (d, J=2.0 Hz, 1H), 4.67 (brs, 2H), 1.56 (s, 9H); 1C NMR (100 MHz, CDCl3): δ 150.4, 150.1, 145.3, 133.5, 131.5, 106.5, 85.0, 27.6.
Reference: [1] Patent: US2015/307476, 2015, A1, . Location in patent: Paragraph 0038-0039
[2] Tetrahedron Letters, 2014, vol. 55, # 9, p. 1528 - 1531
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 39903-01-0 ]

Crizotinib Related Intermediates

Chemical Structure| 141699-59-4

[ 141699-59-4 ]

tert-Butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate

Chemical Structure| 7379-35-3

[ 7379-35-3 ]

4-Chloropyridine hydrochloride

Chemical Structure| 877397-70-1

[ 877397-70-1 ]

(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine

Chemical Structure| 877399-50-3

[ 877399-50-3 ]

tert-Butyl 4-(4-bromo-1H-pyrazol-1-yl)piperidine-1-carboxylate

Chemical Structure| 73183-34-3

[ 73183-34-3 ]

4,4,4',4',5,5,5',5'-Octamethyl-2,2'-bi(1,3,2-dioxaborolane)

Related Functional Groups of
[ 39903-01-0 ]

Bromides

Chemical Structure| 42409-58-5

[ 42409-58-5 ]

5-Bromo-3-methoxypyridin-2-amine

Similarity: 0.92

Chemical Structure| 947249-13-0

[ 947249-13-0 ]

5-Bromo-3-(difluoromethoxy)pyridin-2-amine

Similarity: 0.81

Chemical Structure| 947249-16-3

[ 947249-16-3 ]

5-Bromo-3-methoxy-6-methylpyridin-2-amine

Similarity: 0.81

Chemical Structure| 34950-82-8

[ 34950-82-8 ]

7-Bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine

Similarity: 0.78

Chemical Structure| 754230-78-9

[ 754230-78-9 ]

3-(Benzyloxy)-5-bromopyridin-2-amine

Similarity: 0.76

Alcohols

Chemical Structure| 934758-27-7

[ 934758-27-7 ]

2-Amino-6-bromopyridin-3-ol

Similarity: 0.74

Chemical Structure| 20348-16-7

[ 20348-16-7 ]

2-Amino-6-methylpyridin-3-ol

Similarity: 0.74

Chemical Structure| 34206-49-0

[ 34206-49-0 ]

5-Bromopyridine-2,3-diol

Similarity: 0.74

Chemical Structure| 857429-79-9

[ 857429-79-9 ]

2,5-Dibromopyridin-3-ol

Similarity: 0.73

Chemical Structure| 91420-25-6

[ 91420-25-6 ]

5-Bromo-2-methylpyridin-3-ol

Similarity: 0.72

Amines

Chemical Structure| 42409-58-5

[ 42409-58-5 ]

5-Bromo-3-methoxypyridin-2-amine

Similarity: 0.92

Chemical Structure| 947249-13-0

[ 947249-13-0 ]

5-Bromo-3-(difluoromethoxy)pyridin-2-amine

Similarity: 0.81

Chemical Structure| 947249-16-3

[ 947249-16-3 ]

5-Bromo-3-methoxy-6-methylpyridin-2-amine

Similarity: 0.81

Chemical Structure| 754230-78-9

[ 754230-78-9 ]

3-(Benzyloxy)-5-bromopyridin-2-amine

Similarity: 0.76

Chemical Structure| 934758-27-7

[ 934758-27-7 ]

2-Amino-6-bromopyridin-3-ol

Similarity: 0.74

Related Parent Nucleus of
[ 39903-01-0 ]

Pyridines

Chemical Structure| 42409-58-5

[ 42409-58-5 ]

5-Bromo-3-methoxypyridin-2-amine

Similarity: 0.92

Chemical Structure| 947249-13-0

[ 947249-13-0 ]

5-Bromo-3-(difluoromethoxy)pyridin-2-amine

Similarity: 0.81

Chemical Structure| 947249-16-3

[ 947249-16-3 ]

5-Bromo-3-methoxy-6-methylpyridin-2-amine

Similarity: 0.81

Chemical Structure| 754230-78-9

[ 754230-78-9 ]

3-(Benzyloxy)-5-bromopyridin-2-amine

Similarity: 0.76

Chemical Structure| 934758-27-7

[ 934758-27-7 ]

2-Amino-6-bromopyridin-3-ol

Similarity: 0.74